Kumar S, Hand P H, Marsden H B, Kumar P, Thor A
Christie Hospital and Holt Radium Institute, Manchester, England.
Anticancer Res. 1991 Jul-Aug;11(4):1657-62.
A monoclonal antibody, RAP-5, raised against the 21,000d ras-oncogene product, p21, was used in an immunoperoxidase staining procedure to study the expression of p21 in normal children's and foetal kidneys, pre-malignant lesions and benign and malignant childhood renal tumours with good, moderate or poor prognosis. ras-p21 was expressed in both normal and foetal kidneys but its distribution in renal tumours differed markedly (p less than 0.01). A quantitative liquid competition radioimmunoassay (RIA) was used to determine ras-p21 level in tissue homogenates. The results were expressed as pg of ras-p21 per microgram protein of tissue extract. There were significant differences in the levels of ras-p21 among various renal tissue extracts (p less than 0.05). Generally it emerged that the amount of ras-p21 was greater in both malignant renal tumours and foetal kidneys compared to normal kidneys, pre-malignant lesions and benign renal tumours.
一种针对21000d的ras癌基因产物p21产生的单克隆抗体RAP-5，被用于免疫过氧化物酶染色程序，以研究p21在正常儿童及胎儿肾脏、癌前病变以及预后良好、中等或较差的儿童期良性和恶性肾肿瘤中的表达情况。ras-p21在正常肾脏和胎儿肾脏中均有表达，但其在肾肿瘤中的分布显著不同（p<0.01）。采用定量液体竞争放射免疫测定法（RIA）来测定组织匀浆中ras-p21的水平。结果以每微克组织提取物蛋白中ras-p21的皮克数表示。不同肾脏组织提取物中ras-p21的水平存在显著差异（p<0.05）。总体而言，与正常肾脏、癌前病变和良性肾肿瘤相比，恶性肾肿瘤和胎儿肾脏中ras-p21的量更大。
